A polygenic risk score (PRS) may help identify women who are at a greater risk of developing a future breast cancer after treatment for in situ breast disease, a retrospective study suggests. The ...

The diagnosis of lobular carcinoma in situ (LCIS) can be somewhat confusing. It sounds like a cancer diagnosis, but LCIS is not cancer. It’s a benign condition, but it does increase the risk of ...

Lobular carcinoma in situ, or LCIS, sounds similar to its linguistic cousin DCIS (ductal carcinoma in situ). But its diagnosis is typically considered less worrisome. Rather than being a precancerous ...

A genetic risk score could one day guide more personalized treatment for high-risk women, while sparing low-risk women from unnecessary procedures. A new genetic analysis could help predict whether ...

SAN ANTONIO — Daily use of low-dose (5 mg) tamoxifen (multiple brands) for a shorter-than-usual treatment period (3 years) for patients with ductal carcinoma in situ (DCIS) and other forms of ...

A genetic risk score can help predict which women will develop invasive breast cancer after abnormal cells have been found in their breast tissue, researchers said. Women who scored high on the ...

Quantitative monitoring of circulating epithelial cells for individual therapy control in lung and breast cancer during neoadjuvant treatment, surgery and adjuvant chemotherapy No significant ...

Breast-conserving surgery plus radiation therapy (RT) could be a treatment option for selected patients with extensive, pure ductal carcinoma in situ (DCIS), according to a retrospective study. Among ...